Di-diabody: a novel tetravalent bispecific antibody molecule by design (Q44581936)

4 December 2017

Di-diabody: a novel tetravalent bispecific antibody molecule by design (English)

1 reference

4 December 2017

1 reference

Dan Lu

1

1 reference

4 December 2017

Xenia Jimenez

2

1 reference

4 December 2017

Haifan Zhang

3

1 reference

4 December 2017

Amanda Atkins

4

1 reference

4 December 2017

Laura Brennan

5

1 reference

4 December 2017

Paul Balderes

6

1 reference

4 December 2017

Peter Bohlen

7

1 reference

4 December 2017

Larry Witte

8

1 reference

4 December 2017

Zhenping Zhu

9

1 reference

4 December 2017

1 August 2003

1 reference

Journal of Immunological Methods

4 December 2017

1 reference

4 December 2017

279

1 reference

4 December 2017

1-2

1 reference

4 December 2017

219-232

1 reference

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Bispecific antibodies as novel bioconjugates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Bispecific human IgG by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Toward the production of bispecific antibody fragments for clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Design and production of novel tetravalent bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Vascular endothelial growth factor: molecular and biological aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Monoclonal antibody strategies to block angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

"Diabodies": small bivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Vascular endothelial growth factor and its receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

An efficient route to human bispecific IgG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

A dimeric bispecific miniantibody combines two specificities with avidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

New protein engineering approaches to multivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Introduction: bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Bispecific monoclonal antibodies from hybrid hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Immunotherapeutic perspective for bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Tumor localization and therapeutic potential of an antitumor-anti-CD3 heteroconjugate antibody in human renal cell carcinoma xenograft models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

High level secretion of a humanized bispecific diabody from Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Remodeling domain interfaces to enhance heterodimer formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

An efficient route to the production of an IgG-like bispecific antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2803%2900251-5

10.1016/S0022-1759(03)00251-5

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference